CTLA4 and cancer: Programmed cell death-1 (PD-1), its associated ligand (PD-L1), and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) negatively regulate immune function and are constitute targets for cancer immunotherapy1.